TB-500 for Tendonitis: Research & Healing Protocols

Tendonitis commonly affects the Achilles, patellar, rotator cuff, and elbow tendons. Chronic tendonitis (tendinopathy) involves degenerative changes beyond simple inflammation.

TB-500 is researched because Thymosin Beta-4 plays a natural role in tissue repair. It has been studied extensively in equine medicine for tendon injuries in racehorses, providing a broader evidence base.

TB-500 promotes healing through distinct mechanisms:

• Cell Migration: Upregulates actin, promoting cell migration to injury sites
• Anti-inflammatory: Reduces inflammatory cytokines
• Tissue Remodeling: Promotes organized collagen deposition over scar tissue
• Stem Cell Differentiation: May support differentiation into tenocytes

Relevant research:

• Equine Studies: Widely used in veterinary medicine for horse tendon injuries, with improved ultrasound findings and earlier return to training.
• Wound Healing (Philp et al., 2004): Accelerated wound closure and angiogenesis in animal models.
• Cardiac Repair: Reduced scar formation and promoted functional recovery, demonstrating tissue-remodeling capabilities.

Evidence level: Substantial equine data. Human clinical data for tendons is limited, though Thymosin Beta-4 has been in human trials for other indications.

Common protocols:

• Loading (Weeks 1–4): 2–2.5 mg twice per week (4–5 mg/week total)
• Maintenance (Weeks 5–8): 2 mg once per week
• Injection: Subcutaneous anywhere (TB-500 works systemically)
• Total Cycle: 8–12 weeks

• Week 2–3: Initial pain and stiffness reduction
• Week 4–6: Noticeable functional improvement
• Week 6–8: Significant healing progress
• Week 8–12: Continued remodeling; maximum benefit

TB-500 tends to work slightly slower than BPC-157 for pain relief but may offer superior tissue remodeling.

Ascension Peptides carries research-grade TB-500:

• Third-party HPLC testing with ≥98% purity
• Published COAs for every batch
• Available in 2mg or 5mg vials